##common.pageHeaderLogo.altText##

Original article

Vol. 156 No. 1 (2026)

Diagnostic assessment of first-episode psychosis patients and adherence to German S3 guidelines: a retrospective cross-sectional study

Cite this as:
Swiss Med Wkly. 2026;156:4490
Published
06.01.2026

Summary

 

BACKGROUND: Guidelines for diagnostic work-up in first-episode psychosis (FEP) vary worldwide. The German DGPPN S3 guidelines recommend a comprehensive work-up, including neuroimaging. However, real-world adherence to these recommendations remains unclear. This study examined guideline adherence in a Swiss tertiary psychiatric hospital.

METHODS: We conducted a retrospective cross-sectional study analysing electronic healthcare records of first-episode psychosis patients hospitalised with an ICD-10 chapter F2 diagnosis for the first time between October 2022 and September 2023. We assessed adherence to recommended mandatory DGPPN S3 assessments – neurological examinations, blood analyses, drug screening, MRI – and evaluated completion of optional assessments such as EEG and lumbar puncture.

RESULTS: A total of 68 first-episode psychosis patients were included from 364 patients screened: 44 (64.7%) were men; their median age was 29 (IQR: 23–33) years; 35 (51.5%) were involuntary admissions. Nearly all patients (n = 66 or 97.1%) received thorough neurological examinations and blood analyses, while 56 (82.4%) underwent drug screening (with 35 [44.6%] testing positive for cannabis). MRI was conducted in 38 (55.9%) cases. Non-completion of MRI was mainly due to patient refusal (n = 10 or 14.7%) or early discharge (n = 16 or 23.5%). Optional EEG and lumbar puncture were less frequently performed: in 26 (38.2%) and 4 (5.9%) patients, respectively.

CONCLUSIONS: Overall, guideline adherence was high, particularly for essential diagnostic procedures. However, only around half of the sample underwent MRI imaging, largely because of patient refusal or patient-requested discharge prior to completion of the suggested assessment. These findings highlight the need for optimised diagnostic workflows and enhanced patient education strategies to improve guideline adherence in FEP assessment.

References

  1. 1. Freudenreich O, Schulz SC, Goff DC. Initial medical work-up of first-episode psychosis: a conceptual review. Early Interv Psychiatry. 2009 Feb;3(1):10–8. doi: https://doi.org/10.1111/j.1751-7893.2008.00105.x
  2. 2. Blackman G, Neri G, Al-Doori O, Teixeira-Dias M, Mazumder A, Pollak TA, et al. Prevalence of Neuroradiological Abnormalities in First-Episode Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2023 Oct;80(10):1047–54. doi: https://doi.org/10.1001/jamapsychiatry.2023.2225
  3. 3. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007 Jun;190(6):515–20. doi: https://doi.org/10.1192/bjp.bp.106.024448
  4. 4. AWMF Leitlinienregister [Internet]. [cited 2024 Apr 21]. Available from: https://register.awmf.org/de/leitlinien/detail/038-009
  5. 5. Overview | Structural neuroimaging in first-episode psychosis | Guidance | NICE [Internet]. NICE; 2008 [cited 2024 Apr 21]. Available from: https://www.nice.org.uk/guidance/ta136
  6. 6. 2 Clinical need and practice | Structural neuroimaging in first-episode psychosis | Guidance | NICE [Internet]. NICE; 2008 [cited 2024 Apr 21]. Available from: https://www.nice.org.uk/guidance/ta136/chapter/2-Clinical-need-and-practice
  7. 7. American Psychiatric Association Practice Guidelines [Internet]. Psychiatry Online. [cited 2024 Apr 21]. Available from: https://www.psychiatryonline.org/guidelines
  8. 8. Forbes M, Stefler D, Velakoulis D, Stuckey S, Trudel JF, Eyre H, et al. The clinical utility of structural neuroimaging in first-episode psychosis: A systematic review. Aust N Z J Psychiatry. 2019 Nov;53(11):1093–104. doi: https://doi.org/10.1177/0004867419848035
  9. 9. Borgwardt SJ, Radue EW, Götz K, Aston J, Drewe M, Gschwandtner U, et al. Radiological findings in individuals at high risk of psychosis. J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):229–33. doi: https://doi.org/10.1136/jnnp.2005.069690
  10. 10. Perrottelli A, Giordano GM, Brando F, Giuliani L, Mucci A. EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review [Internet]. Front Psychiatry. 2021 May;12:653642. [cited 2024 Apr 21] Available from: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.653642/full 10.3389/fpsyt.2021.653642
  11. 11. Pollak TA, Lennox BR. Time for a change of practice: the real-world value of testing for neuronal autoantibodies in acute first-episode psychosis. BJPsych Open. 2018 Jul;4(4):262–4. doi: https://doi.org/10.1192/bjo.2018.27
  12. 12. Drosos P, Brønnick K, Joa I, Johannessen JO, Johnsen E, Kroken RA, et al. One-Year Outcome and Adherence to Pharmacological Guidelines in First-Episode Schizophrenia: Results From a Consecutive Cohort Study. J Clin Psychopharmacol. 2020;40(6):534–40. doi: https://doi.org/10.1097/JCP.0000000000001303
  13. 13. Jin H, Tappenden P, MacCabe JH, Robinson S, McCrone P, Byford S. Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. Br J Psychiatry. 2021 Apr;218(4):224–9. doi: https://doi.org/10.1192/bjp.2020.241
  14. 14. Ito S, Ohi K, Yasuda Y, Fujimoto M, Yamamori H, Matsumoto J, et al. Better adherence to guidelines among psychiatrists providing pharmacological therapy is associated with longer work hours in patients with schizophrenia. Schizophrenia (Heidelb). 2023 Nov;9(1):78. doi: https://doi.org/10.1038/s41537-023-00407-3
  15. 15. Petrakis M, Hamilton B, Penno S, Selvendra A, Laxton S, Doidge G, et al. Fidelity to clinical guidelines using a care pathway in the treatment of first episode psychosis. J Eval Clin Pract. 2011 Aug;17(4):722–8. doi: https://doi.org/10.1111/j.1365-2753.2010.01548.x
  16. 16. Corp IB. Released 2023. IBM SPSS Statistics for Windows, Version 29.0.2.0 Armonk, NY: IBM Corp.
  17. 17. Reilly J, Newton R, Dowling R. Implementation of a first presentation psychosis clinical pathway in an area mental health service: the trials of a continuing quality improvement process. Australas Psychiatry. 2007 Feb;15(1):14–8. doi: https://doi.org/10.1080/10398560601083027
  18. 18. Forbes M, Stuckey S, Kisely S. Concerns Regarding Strength of Conclusions in Systematic Review and Meta-Analysis of Neuroradiological Abnormalities in First-Episode Psychosis. JAMA Psychiatry. 2024 Jan;81(1):107. doi: https://doi.org/10.1001/jamapsychiatry.2023.4390
  19. 19. Blackman G, Kempton MJ, McGuire P. Concerns Regarding Strength of Conclusions in Systematic Review and Meta-Analysis of Neuroradiological Abnormalities in First-Episode Psychosis-Reply. JAMA Psychiatry. 2024 Jan;81(1):109. doi: https://doi.org/10.1001/jamapsychiatry.2023.4399
  20. 20. Omlor W, Rabe F, Fuchs S, Cecere G, Homan S, Surbeck W, et al. Estimating multimodal brain variability in schizophrenia spectrum disorders: A worldwide ENIGMA study. bioRxiv. 2023 Nov 2;2023.09.22.559032.
  21. 21. Bellani M, Perlini C, Zovetti N, Rossetti MG, Alessandrini F, Barillari M, et al. Incidental findings on brain MRI in patients with first-episode and chronic psychosis. Psychiatry Res Neuroimaging. 2022 Oct;326:111518. doi: https://doi.org/10.1016/j.pscychresns.2022.111518
  22. 22. Baier M. Insight in schizophrenia: a review. Curr Psychiatry Rep. 2010 Aug;12(4):356–61. doi: https://doi.org/10.1007/s11920-010-0125-7
  23. 23. Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs. 2007;21(2):129–41. doi: https://doi.org/10.2165/00023210-200721020-00004
  24. 24. Lincoln TM, Lüllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull. 2007 Nov;33(6):1324–42. doi: https://doi.org/10.1093/schbul/sbm002
  25. 25. Ertem MY, Duman ZÇ. The effect of motivational interviews on treatment adherence and insight levels of patients with schizophrenia: A randomized controlled study. Perspect Psychiatr Care. 2019 Jan;55(1):75–86. doi: https://doi.org/10.1111/ppc.12301
  26. 26. Panchalingam J, Horisberger R, Corda C, Kleisner N, Krasnoff J, Burrer A, et al. Motivational Interviewing in Patients with Acute Psychosis: First Insights from a Pilot Randomized Controlled Trial. 2024 [cited 2025 Jan 14]; Available from: https://osf.io/x3mub/download